Trulicity (Dulaglutide)

Trulicity doesn’t get the media attention that Ozempic and Mounjaro attract. It’s not the one celebrities name-drop. It’s not the one driving social media discourse. But for several years running, it was one of the most prescribed GLP-1 medications in the world — and the clinical evidence behind it is more substantial than many people realize.

Trulicity is a weekly injection for Type 2 diabetes made by Eli Lilly. It was approved three years before Ozempic and built a huge patient base on the strength of its ease of use and cardiovascular data. The landscape has shifted since then — newer medications produce more weight loss and more headlines — but Trulicity remains a relevant option for specific patients.

This page covers what Trulicity is, what it does well, how it compares to the newer options honestly, and who it’s best suited for today.

---

The Basics

Trulicity is made by Eli Lilly. The active ingredient is dulaglutide — a GLP-1 receptor agonist that’s designed differently from semaglutide or liraglutide at the molecular level.

Here’s the difference: semaglutide and liraglutide are modified versions of the natural GLP-1 hormone. Dulaglutide takes a different approach — it fuses a GLP-1 molecule to a piece of a human antibody (called an IgG4 Fc fragment). Think of it like attaching a small buoy to the GLP-1 molecule. The buoy makes it larger, which means the body clears it more slowly. This gives dulaglutide a half-life of about 5 days — long enough for once-weekly dosing.[1]

FDA-approved indications:

1. Type 2 diabetes — to improve blood sugar control alongside diet and exercise (September 2014)
2. Cardiovascular risk reduction — to reduce the risk of major cardiovascular events in adults with Type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors (February 2020)
3. Pediatric Type 2 diabetes — for children aged 10 and older (June 2022)

What Trulicity is NOT approved for: weight management. Unlike semaglutide (Wegovy) and tirzepatide (Zepbound), there is no weight management counterpart for dulaglutide. It does produce some weight loss, but significantly less than the newer medications, and it’s only approved for diabetes.[2]

---

How It’s Delivered

Trulicity uses a single-dose, pre-filled pen — and its pen design was considered one of the most user-friendly when it launched.

The Pen

The Trulicity pen is a ready-to-use autoinjector. There’s no need to attach a needle, dial a dose, or see the needle at any point. You:

1. Remove the gray base cap
2. Place the pen flat against your skin (abdomen, thigh, or upper arm)
3. Press and hold the green injection button
4. Wait for two clicks — the first means the injection has started, the second means it’s done

The needle is hidden inside the pen during the entire process. For people with needle anxiety, this design is a genuine advantage over pens that require you to attach and see the needle.[3]

Each pen delivers one fixed dose — no dialing. Each box contains 4 pens (one month’s supply at one injection per week). The injection can be done any day of the week, at any time, with or without food.

---

Dosing Schedule

Trulicity offers four dose levels:

Key things to know:

• Unlike most other GLP-1 medications, Trulicity’s starting dose (0.75 mg) IS a therapeutic dose — it actually provides blood sugar benefit from day one. Some people stay at 0.75 mg if their blood sugar response is sufficient.
• The 3 mg and 4.5 mg doses were added later (approved in 2020) to give providers more room for dose optimization. Before that, Trulicity maxed out at 1.5 mg.
• The 3 mg and 4.5 mg doses produce modestly more weight loss than the lower doses — an important addition for patients who needed more effect.
• If you miss a dose, take it within 3 days. If more than 3 days have passed, skip it and take the next one on your regular day.[4]

---

What the Research Shows

Trulicity’s evidence base is extensive — it’s been tested in more than a dozen clinical trials involving over 30,000 patients. The key trials fall into two categories: the AWARD program (blood sugar control) and the REWIND trial (cardiovascular outcomes).

Blood Sugar Control: The AWARD Trials

The AWARD trial program compared Trulicity head-to-head against multiple other diabetes medications:

• AWARD-1: Trulicity 1.5 mg reduced HbA1c by 1.51% — outperforming exenatide (another GLP-1)
• AWARD-3: Superior to metformin alone
• AWARD-5: Superior to sitagliptin (Januvia) at both 26 and 52 weeks
• AWARD-6: Just as effective as liraglutide 1.8 mg (Victoza) for blood sugar, with comparable weight loss
• AWARD-11: The higher doses showed incremental benefit — 3 mg reduced HbA1c by 1.7%, and 4.5 mg by 1.9%, at 36 weeks[5]

Across the AWARD program, Trulicity consistently reduced HbA1c by 1.0–1.9% depending on the dose and trial population. The percentage of patients reaching HbA1c below 7% ranged from about 55-80%.

How It Compares to Semaglutide: SUSTAIN 7

This is the comparison people ask about. SUSTAIN 7 was a head-to-head trial between Trulicity (0.75 mg and 1.5 mg) and Ozempic (0.5 mg and 1 mg) in 1,201 patients with Type 2 diabetes over 40 weeks.

The result: semaglutide won on both blood sugar and weight loss.

Semaglutide produced about double the weight loss and better blood sugar reduction. Side effect profiles were comparable between the two medications.[6]

This trial is part of why Trulicity’s market share has declined since semaglutide became widely available. But there are nuances worth understanding — which we’ll get to in the “who it’s best for” section.

The REWIND Trial: Heart Protection

REWIND is Trulicity’s most important trial and one of its strongest selling points.

What makes REWIND different from other GLP-1 cardiovascular trials (like LEADER for liraglutide or SELECT for semaglutide) is its population. Most cardiovascular outcome trials only enrolled patients with established heart disease. REWIND enrolled a broader population — including patients with cardiovascular risk factors but who hadn’t yet had a heart attack or stroke.

• Who: 9,901 adults with Type 2 diabetes. About 69% had cardiovascular risk factors only — meaning they hadn’t yet had a cardiovascular event
• How long: Median 5.4 years — the longest follow-up of any GLP-1 cardiovascular trial
• Dose: Trulicity 1.5 mg weekly

The results:[7]

• Major cardiovascular events (heart attack, stroke, or cardiovascular death): reduced by 12%
• Non-fatal stroke alone: reduced by 24%

The 12% reduction in cardiovascular events is numerically smaller than what LEADER showed for liraglutide (13%) or SELECT showed for semaglutide (20%). But REWIND demonstrated this benefit in a broader, lower-risk population — meaning the heart protection wasn’t limited to people who’d already had heart attacks. That’s a meaningful distinction.

Weight Loss

Trulicity does produce weight loss, but the numbers are modest compared to the newer medications:

For comparison: Ozempic at 1 mg produces about 13 lbs of weight loss, and Mounjaro at 15 mg produces about 25 lbs — both in diabetes populations. Trulicity’s weight loss is real, but it’s not the medication’s primary strength.[8]

---

Side Effects

Trulicity’s side effect profile follows the same GI pattern as other GLP-1 medications, but the overall rates tend to be comparable to or slightly lower than semaglutide at equivalent efficacy levels.

The Numbers

About 2-5% of patients stopped Trulicity due to GI side effects across the trials — a relatively low discontinuation rate. Most GI symptoms occurred during the early weeks and improved over time.[9]

The Boxed Warning

Like all GLP-1 medications, Trulicity carries an FDA boxed warning about thyroid C-cell tumors based on animal studies. The same caveats apply: not confirmed in humans, but it means Trulicity should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

---

Who Trulicity Is Best For

The honest question in 2026 is: with semaglutide and tirzepatide available, who should still be on Trulicity? The answer is more nuanced than “nobody.”

People who are doing well on it already. If your blood sugar is well-controlled, you’re tolerating it fine, and you’re not looking for dramatically more weight loss, switching for the sake of switching doesn’t make medical sense. “If it ain’t broke” is a valid clinical philosophy.

People who value the pen design. Trulicity’s hidden-needle autoinjector is genuinely easier to use than most other GLP-1 pens. For people with significant needle anxiety or dexterity challenges, the Trulicity pen requires the fewest steps and the least needle exposure.

People whose insurance covers it but not the alternatives. Insurance formularies vary widely. Some plans still have Trulicity as their preferred GLP-1 medication with better coverage or lower copays than semaglutide or tirzepatide options.

People who need cardiovascular protection beyond established heart disease. REWIND’s broader population — including patients with risk factors who haven’t yet had events — gives Trulicity a unique data profile for primary prevention.

Pediatric patients. Trulicity is one of the few GLP-1 medications approved for children aged 10 and older with Type 2 diabetes.

When It Might Be Time to Switch

If your blood sugar isn’t well-controlled at the maximum Trulicity dose, or if significant weight loss is an important goal, the newer medications offer more. Discuss this with your provider — the decision should be based on your specific response, not just headline comparisons.

---

Cost and Access

What Trulicity Costs

The Lilly Savings Card

If you have commercial insurance that covers Trulicity, Eli Lilly’s savings card brings your copay to as little as $25 per month. The card provides up to $100 in savings per one-month supply.[10]

Who qualifies: People with commercial insurance and a prescription for an FDA-approved use. Who doesn’t: Medicare, Medicaid, TRICARE, VA, and other government insurance — federal rules prohibit manufacturer savings cards for government programs.

Medicare Coverage

Medicare Part D covers Trulicity for Type 2 diabetes. Copays vary by plan. The Inflation Reduction Act’s annual out-of-pocket cap may help reduce costs for Medicare beneficiaries.

If You Can’t Afford It

Eli Lilly’s Lilly Cares Patient Assistance Program provides medications at no cost for eligible uninsured patients. Contact Lilly Cares at 1-800-545-6962 or visit lillycares.com.

---

Storage

Since each pen is single-dose, there’s no “days after first use” window to track. The 14-day room temperature limit means you can take a pen out of the fridge about two weeks before you plan to use it, but don’t leave an entire month’s supply sitting on the counter.[11]

---

The Bottom Line

Trulicity is a solid, well-proven GLP-1 medication for Type 2 diabetes with cardiovascular benefits demonstrated in one of the broadest patient populations ever studied. Its pen design is arguably the easiest to use in the class, and it has approvals spanning adults, children, and cardiovascular risk reduction.

Is it the most powerful GLP-1 available? No. Semaglutide produces better blood sugar control and more weight loss. Tirzepatide produces even more. But Trulicity has years of established use, a comfortable pen experience, and clinical data that holds its own where it matters most: blood sugar control and heart protection.

The question isn’t whether Trulicity is a good medication — it is. The question is whether it’s the right one for you right now. If you’re doing well on it, there may be no reason to change. If you’re not getting the results you need, the newer options offer more. Either way, that’s a conversation for you and your provider to have with the full picture in front of you.

---